Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adipose-derived stem cells versus Synvisc for knee osteoarthritis
ACTRN12611000274976Phase 3Withdrawn
- Sponsor
- Kade Paterson
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of adipose derived mesenchymal stromal cells and sodium hyaluronate in knee osteoarthritis (OA) (2 arms), sponsored by Kade Paterson. Primary endpoints: Pain measured using 100 mm Visual Analogue Score and Knee Injury and Osteoarthritis Outcome Score. Planned start May 2011; status: withdrawn.
02
Drugs
adipose derived mesenchymal stromal cellssodium hyaluronate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12611000274976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000274976.